BioAge Status
The company raised $10.9 million of Series A venture funding in a deal led by Andreessen Horowitz on July 28, 2017, putting the company's pre-money valuation at $32.7 million. Felicis Ventures, AME Cloud Ventures, Pear, Caffeinated Capital, Elad Gil, Farzad Nazem and other undisclosed investors also participated in the round. The company will use the funds to build the team, refine and test its signatures of aging and begin in vivo evaluation of drug candidates.
Add a review